The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors

被引：8
|
作者：
Agboola, Foluso [1 ]
Rind, David M. [1 ]
Walton, Surrey M. [2 ]
Herron-Smith, Serina [1 ]
Quach, Danny [2 ]
Pearson, Steven D. [1 ]
机构：
[1] Inst Clin & Econ Review, Boston, MA 02109 USA
[2] Univ Illinois, Ctr Pharmacoepidemiol & Pharmacoecon Res, Chicago, IL USA
来源：
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY | 2021年 / 27卷 / 05期
关键词：
RECOMBINANT FACTOR-VIII;
D O I：
10.18553/jmcp.2021.27.5.667
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：667 / 673
页数：7
相关论文
共 50 条
  • [31] Emicizumab for hemophilia A with factor VIII inhibitors
    Young, Guy
    Callaghan, Michael
    Dunn, Amy
    Kruse-Jarres, Rebecca
    Pipe, Steven
    EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (11) : 835 - 846
  • [32] Emicizumab Prophylaxis in Hemophilia A with Inhibitors REPLY
    Oldenburg, Johannes
    Levy, Gallia G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (22): : 2194 - 2195
  • [33] SAFETY AND EFFICACY OF VALOCTOCOGENE ROXAPARVOVEC GENE TRANSFER FOR SEVERE HEMOPHILIA A: AN UPDATE FROM 4 YEARS AFTER TREATMENT
    Leavitt, Andrew D.
    Mahlangu, Johnny
    Symington, Emily
    Quon, Doris V.
    Giermasz, Adam
    Key, Nigel S.
    Pipe, Steven W.
    Madan, Bella
    Chou, Sheng-Chieh
    Klamroth, Robert
    Mason, Jane
    Peyvandi, Flora
    Yu, Hua
    Robinson, Tara M.
    Ozelo, Margareth C.
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 100 : 72 - 73
  • [34] Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real-world clinical experience
    Klamroth, Robert
    Gottstein, Saskia
    HAEMOPHILIA, 2024, 30 (05) : 1247 - 1249
  • [35] AN ITALIAN PHARMACOUTILIZATION ANALYSIS IN PATIENTS WITH HEMOPHILIA A WITH AND WITHOUT INHIBITORS AFTER SWITCHING TO EMICIZUMAB
    Perrone, V
    Leogrande, M.
    Motta, L.
    Tempre, R.
    Bendinelli, S.
    Ferrario, M.
    Esposti, L. Degli
    VALUE IN HEALTH, 2024, 27 (12)
  • [36] FIRST NEUTRALIZING ANTIDRUG ANTIBODY TO EMICIZUMAB IN A PATIENT WITH SEVERE HEMOPHILIA A WITHOUT INHIBITORS
    Guerrera, Michael F.
    Kizilocak, Hande
    Varela, Carly
    Guelcher, Christine
    Godby, Lauren
    Young, Guy
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : E43 - E43
  • [37] A BOY WITH HEMOPHILIA A WITHOUT INHIBITORS IN PROPHYLAXIS WITH EMICIZUMAB IN PORTUGAL: IS HE THE FIRST OF MANY?
    Campanico, S.
    Catarino, C.
    Rodrigues, F.
    Pereira, A.
    HAEMOPHILIA, 2022, 28 : 35 - 35
  • [38] Peri-operative hemostatic management of tooth extraction in patients with hemophilia A, with and without inhibitors, receiving emicizumab prophylaxis
    Yagyuu, Takahiro
    Furukawa, Shoko
    Zaizen, Miki
    Yata, Sachiko
    Imada, Mitsuhiko
    Nogami, Keiji
    Kirita, Tadaaki
    HAEMOPHILIA, 2023, 29 (01) : 172 - 179
  • [39] COST-CONSEQUENCE ANALYSIS OF EMICIZUMAB PROPHYLAXIS FOR SEVERE HEMOPHILIA A PATIENTS WITHOUT INHIBITORS
    Cortesi, P. A.
    Castaman, G.
    Mantovani, L. G.
    VALUE IN HEALTH, 2020, 23 : S696 - S696
  • [40] Reliable Routine Prophylaxis, Relief for Patients Clinical Experience with Emicizumab in Hemophilia A without Inhibitors
    Neubacher, Daniel
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2019, 46 (04) : 294 - 297
12345